



New Drugs October 2010

(Original New Drug Applications: FDA)

Generic Name	Trade Name	Indication(s)	CPG Action/Date
May 2010			
Velaglucerase Alfa Injection Formulary Pg. 10	VPRIV	<i>Endocrine and Metabolic Agents:</i> Gaucher disease: Long term enzyme replacement therapy.	10/18/10 CTP Holder may prescribe.
Collagenase Clostridium Histolyticum Injection Formulary Pg. 22	Xiaflex	<i>Dermatologic Agents: Enzyme Preparations.</i> Treatment of adult patients with Dupuytren contracture with a palpable cord.	10/18/10 CTP Holder MAY NOT prescribe.
Gadofosveset Trisodium Injection Formulary Pg. 26	Ablavar	<i>Diagnostic Aids: In Vivo Diagnostic Aids.</i> Contrast agent for magnetic resonance angiography.	10/18/10 CTP Holder may prescribe.
June 2010			
None			
July 2010			
None			
August 2010			
Denosumab Injection Formulary Pg. 22	Prolia	<i>Biologic and Immunologic Agents: Monoclonal Antibodies.</i> Indication for treatment of osteoporosis.	10/18/10 Physician Initiated/Physician Consult.
Sipuleucel-T Injection Formulary Pg. 26	Provenge	<i>Antineoplastic Agents: Miscellaneous Antineoplastics.</i> Indication for treatment of prostate cancer.	10/18/10 CTP Holder MAY NOT prescribe.
Hexaminolevulinate Hydrochloride Intrevesical Formulary Pg. 26	Cysview	<i>Diagnostic Aids: In Vivo Diagnostic Aids.</i> Indication for detection of bladder cancer.	10/18/10 CTP Holder may prescribe.
September 2010			
Cabazitaxel Injection Formulary Pg. 24	Jevtana	<i>Antineoplastic Agents: Antimitotic Agents.</i> Indication for treatment of prostate cancer.	10/18/10 CTP Holder MAY NOT prescribe.

New Drugs Indications/ Warnings October 2010

(New Drug Indications/ Black Box Warnings: FDA

Generic Name	Trade Name	Indication(s)	CPG Action/Date
May 2010			
Tiotropium Bromide Inhalation Formulary Pg. 13	Spiriva	<i>Respiratory Agents: Bronchodilators.</i> New indication to reduce exacerbations in COPD patients.	Current: CTP Holder MAY prescribe. 10/18/10 No Change.
Varenicline Tartrate Oral Formulary Pg. 18	Chantix	<i>Central Nervous System Agents: Smoking Deterrants.</i> New black box warning regarding potential for serious neuropsychiatric events	Current: CTP Holder MAY prescribe. 10/18/10 No Change.
June 2010			
Deferasirox Oral Formulary Pg. 10	Exjade	<i>Endocrine and Metabolic Agents: Detoxification Agents.</i> New black box warning indicating my cause renal impairment and failure, hepatic impairment and failure, and GI hemorrhage.	Current: CTP Holder MAY NOT prescribe. 10/18/10 No Change.
Hydromorphone Hydrochloride Oral Formulary Pg. 15	Dilaudid	<i>Central Nervous System Agents: Opioid Analgesics: Schedule II Opioids.</i> New black box warning regarding potential for abuse and risk of fatal overdose.	Current: CTP Holder MAY prescribe. Schedule II restrictions apply. 10/18/10 No Change.
Rho (D) Immune Globulin (Human) (Rho[D] IGIV) Injection Formulary Pg. 22	WinRho SDF	<i>Biologic and Immunologic Agents: Immune Globulins.</i> New black box warning regarding potential to develop intravascular hemolysis leading to death.	Current: CTP Holder MAY prescribe. 10/18/10 Change to Physician Initiated/ Physician Consult.
July 2010			
Clopidogrel Bisulfate Oral Formulary Pg. 6	Plavix	<i>Hematological Agents: Antiplatelet Agents: Aggregation Inhibitors.</i> New black box warning indicating diminished effectiveness in poor metabolizers.	Current: CTP Holder MAY prescribe. 10/18/10 No Change.

Rifaximin Oral Formulary Pg. 22	Xifaxan	<i>Anti-Infectives, Systemic:</i> New indication for reduction in risk of hepatic encephalopathy recurrence	Current: 10/18/10 CTP Holder may prescribe.
Human Papillomavirus Quadrivalent Vaccine, Recombinant Injection Formulary Pg, 22	Gardasil	<i>Biologic/Immunologic Agents: Agents For Active Immunizations.</i> New indication for prevention of genital warts in boys and men 9 through 26 years of age.	Current: CTP Holder MAY prescribe. 10/18/10 No Change.
August 2010			
Propylthiouracil Oral Formulary Pg. 9	Propylthiouracil	<i>Endocrine and Metabolic Agents: Thyroid Drugs: Anti-thyroid Agents.</i> New black box warning indicating risk for hepatotoxicity.	Current: CTP Holder MAY prescribe. 10/18/10 No Change.
September 2010			
Iodine Products Oral Formulary Pg. 9	Iosat, ThyroSafe, ThyroShield	<i>Endocrin and Metabolic Agents: Thyroid Drugs.</i> New black box warning indicating that this drug should only be used during nuclear radiation when recommended by a public official.	Current: 10/18/10 CTP Holder may prescribe.

Formulary Revision Request October 2010

(Original New Drug Applications: FDA)

Generic Name	Trade Name	Indication(s)	CPG Action/Date
Formulary Review Revision Request from Michelle Bagby NP			
Treprostinil Formulary Pg. 6	Remodulin	<i>Cardiovascular Agents: Vasodilators: Peripheral Vasodilators.</i> Indication for treatment of pulmonary artery hypertension. Requesting Physician Consult.	Current: CTP Holder MAY NOT prescribe. 10/18/10 Change to Physician Initiated/ Physician Consult in specialty clinic.
Epoprostenol Formulary Pg. 12	Flolan	<i>Cardiovascular Agents: Vasodilators: Peripheral Vasodilators.</i> Indication for treatment of pulmonary hypertension. Requesting Physician Consult.	Current: IV: Acute Care CTP Holder MAY prescribe. 10/18/10 Change to Physician Initiated/ Physician Consult in specialty clinic.
Formulary Review Revision Request from Amber S. Lanich ACNP			
Treprostinil Formulary Pg. 6	Remodulin	<i>Cardiovascular Agents: Vasodilators: Peripheal Vasodilators.</i> Indication for treatment of pulmonary artery hypertension. Requesting Physician Consult.	Current: CTP Holder MAY NOT prescribe. 10/18/10 Change to Physician Initiated/ Physician Consult in specialty clinic.
Formulary Review Revision Request from Christine Dombroski RNC NP			
Tranexamic Acid Formulary Pg. 7	Lysteda	<i>Hematologic Agent: Hemostatics.</i> Indication for heavy menstrual bleeding. Requesting CTP Holder May Prescribe.	Current: CTP Holder MAY NOT prescribe. 10/18/10 Change to Physician Initiated/ Physician Consult.
Formulary Review Revision Request from Teresa J. Lampe NP-C			

<p>Tranexamic Acid Formulary Pg. 7</p>	<p>Lysteda</p>	<p><i>Hematologic Agent: Hemostatics.</i> Indication for heavy menstrual bleeding. Requesting CTP Holder May Prescribe.</p>	<p>Current: CTP Holder MAY NOT prescribe. 10/18/10 Change to Physician Initiated/Physician Consult.</p>
<p>Formulary Review Revision Request from Joyce Perry CNP, Kellie Hoffman CNP, Donna Owen CNP</p>			
<p>Phentolamine Solution Formulary Pg.12</p>	<p>Regitine, Oraverse</p>	<p><i>Cardiovascular Agents: Agents for Pheochromocytoma.</i> Indication for pheochromocytoma, dermal necrosis. Unlabeled used for hypertensive crises. It has also been used in combination with papaverine as an intracavernous injection for impotence. Requesting CTP Holder May Prescribe ICI- Intracavernous Injection.</p>	<p>Current: CTP Holder MAY NOT prescribe. 10/18/10 No Change.</p>
<p>Papaverine Formulary Pg. 12</p>	<p>Papacon, Para-Time SR, Pavacot</p>	<p><i>Cardiovascular Agents: Vasodilators: Peripheral Vasodilators.</i> Indication for ischemia. Requesting CTP Holder May Prescribe ICI- Intracavernous Injection.</p>	<p>Current: PO: CTP Holder MAY Prescribe. 10/18/10 No Change.</p>